secwatch.observer — SEC 8-K summary
======================================

Issuer:     Trevi Therapeutics, Inc. (TRVI)
CIK:        0001563880
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0001564590-22-029123
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Trevi Q2 net loss narrows to $8.1M; Haduvio achieves all endpoints in Phase 2b/3 prurigo nodularis trial
--------------------------------------------------------------------------------

- Q2 2022 net loss of $8.1M ($9.8M in Q2 2021); cash and securities $78.9M.
- Phase 2b/3 PRISM trial met primary endpoint (25% vs 14% WI-NRS 4-point reduction, p=0.0157) and all key secondary endpoints with statistical significance.
- Completed $55M private placement in April 2022 to fund clinical development of Haduvio.
- Topline data from Phase 2 CANAL chronic cough in IPF trial expected Q3 2022; FDA meeting scheduled for this quarter.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563880/000156459022029123/0001564590-22-029123-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563880/000156459022029123/trvi-8k_20220811.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-029123

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer